⌕
Vera Therapeutics · VERA · Nasdaq
Tenet 41 · Weak
Compare
$26.20−2.85%At closeTenet 41 · Weak
$26.20−0.77 (−2.85%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Vera Therapeutics (VERA) Stock

Vera Therapeutics (VERA) closed at $26.20 on Nov 17, 2026; its Tenet Score is 41 of 100 against 340 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

32 figures withheld by our checks. Each blank figure names its reason.

Key stats

Close
$26.20
Nov 17, 2026
Market cap
$1.9B
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
26.38 – 56.05
low → high · as of close, Nov 16, 2026
Tenet Score
41/100
Weak · 340 Healthcare peers

Industry: Drugs

Vera Therapeutics Inc scores 41/100. Weak. Strongest on financial health, quality is the soft spot versus 340 Healthcare peers. Insufficient inputs: Tenet 41 is built from 3 of 4 pillars, from 40% of its inputs. The pillars showing a dash had no data.

Tenet Score · vs sector

n=340
41/ 100
Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
37
Quality
16
Health
70
Growth
—

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Growth omitted — no data yet.
ValueDQualityFHealthBGrowth—MomentumD
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
5.9×
Sep 30, 2026 balance sheet
P/S
189.7×
price to sales, TTM through Sep 30, 2026 · as of close, Nov 16, 2026
ROE
−113%
TTM through Sep 30, 2026
Operating margin
—
no operating margin on file
Net margin
—
Not meaningful: revenue is too small to measure a margin against.
Current ratio
7.91
Sep 30, 2026 balance sheet
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Vera Therapeutics Inc

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-admin…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=340) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 62 US ETFs · top wrappers by weightSee all ETFs holding VERA →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 16, 2026.

What sector and industry is Vera Therapeutics in?

Vera Therapeutics is in the Healthcare sector and the Drugs industry.

What is Vera Therapeutics' Tenet Score?

Vera Therapeutics' Tenet Score is 41 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.